"This is fantastic for a phase I study," says Vivek Subbiah, the M.D. Anderson researcher who ran the trial with funding from BluePrint, at a press conference. "I do a lot of phase I studies."
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2018/04/15/blueprint-medicines-gene-drug-impresses-in-early-study/
via IFTTT
No comments:
Post a Comment